
TYRA
Tyra Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.230
Open
10.790
VWAP
10.96
Vol
213.80K
Mkt Cap
588.15M
Low
10.4355
Amount
2.34M
EV/EBITDA(TTM)
--
Total Shares
52.54M
EV
269.21M
EV/OCF(TTM)
--
P/S(TTM)
--
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Show More
6 Analyst Rating

173.06% Upside
Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 30.20 USD with a low forecast of 28.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy

173.06% Upside
Current: 11.060

Low
28.00
Averages
30.20
High
33.00

173.06% Upside
Current: 11.060

Low
28.00
Averages
30.20
High
33.00
Piper Sandler
Allison Bratzel
Overweight
initiated
$33
2025-05-21
Reason
Piper Sandler
Allison Bratzel
Price Target
$33
2025-05-21
initiated
Overweight
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-03-31
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$30
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-02-18
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$30
2025-02-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-01-13
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$30
2025-01-13
Reiterates
Strong Buy
Reason
UBS
Eliana Merle
Strong Buy
Initiates
$28
2025-01-07
Reason
UBS
Eliana Merle
Price Target
$28
2025-01-07
Initiates
Strong Buy
Reason
UBS analyst Eliana Merle initiated coverage of Tyra Biosciences with a Buy rating and $28 price target. Tyra Biosciences is a clinical-stage biotech company with a drug, TYRA-300, in development for bladder cancer and a genetic form of short stature, achondroplasia, with many health complications, the analyst tells investors in a research note. The firm thinks TYRA-300 could have improved efficacy and safety vs. Fibroblast Growth Factor Receptor inhibitors that also inhibit FGFR1, 2 and 4, and thinks the long-term opportunity for TYRA-30 in both oncology and growth disorders beyond achondroplasia is larger than appreciated.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Maintains
$32 → $30
2024-11-11
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$32 → $30
2024-11-11
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Tyra Biosciences Inc (TYRA.O) is -4.83, compared to its 5-year average forward P/E of -8.90. For a more detailed relative valuation and DCF analysis to assess Tyra Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-8.90
Current PE
-4.83
Overvalued PE
-4.27
Undervalued PE
-13.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.42
Current EV/EBITDA
-1.92
Overvalued EV/EBITDA
13.24
Undervalued EV/EBITDA
-20.08
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+42.68%
-31.85M
Operating Profit
FY2025Q1
YoY :
+54.72%
-28.15M
Net Income after Tax
FY2025Q1
YoY :
+34.29%
-0.47
EPS - Diluted
FY2025Q1
YoY :
+14.93%
-25.47M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 745.3% over the last month.
Sold
0-3
Months
628.3K
USD
5
3-6
Months
74.3K
USD
1
6-9
Months
2.5M
USD
10
0-12
Months
5.7M
USD
14
Bought
0-3
6
15.3M
USD
Months
3-6
0
0.0
USD
Months
6-9
1
19.8M
USD
Months
0-12
1
151.9K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
717.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
1.8M
Volume
Months
3-6
2
3.8M
Volume
Months
6-9
4
3.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 745.3% over the last month.
Sold
0-3
Months
628.3K
USD
5
3-6
Months
74.3K
USD
1
6-9
Months
2.5M
USD
10
0-12
Months
5.7M
USD
14
Bought
0-3
6
15.3M
USD
Months
3-6
0
0.0
USD
Months
6-9
1
19.8M
USD
Months
0-12
1
151.9K
USD
Months
TYRA News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
08:07:34
Tyra Biosciences says first patient dosed in Phase 2 study of TYRA-300

2025-05-08 (ET)
2025-05-08
16:21:54
Tyra Biosciences reports Q1 EPS (47c), consensus (48c)

2025-05-06 (ET)
2025-05-06
14:14:54
Oncology stocks 'bearing the brunt' of Prasad news, says Oppenheimer

Sign Up For More Events
Sign Up For More Events
News
1.0
07-21PRnewswireTyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
9.0
07-08PRnewswireTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
4.0
07-01BenzingaHC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target
Sign Up For More News
People Also Watch

ICLK
iClick Interactive Asia Group Ltd
0
USD
+9.09%

SCVL
Shoe Carnival Inc
22.280
USD
+0.91%

OSBC
Old Second Bancorp Inc
17.850
USD
+0.39%

ADV
Advantage Solutions Inc
1.600
USD
+6.67%

GCT
GigaCloud Technology Inc
24.070
USD
+0.25%

BVS
Bioventus Inc
6.570
USD
+2.66%

GLDD
Great Lakes Dredge & Dock Corp
11.550
USD
+1.49%

TSAT
Telesat Corp
26.100
USD
-2.17%

VTS
Vitesse Energy Inc
24.280
USD
-0.94%

IE
Ivanhoe Electric Inc
11.630
USD
+0.87%
FAQ

What is Tyra Biosciences Inc (TYRA) stock price today?
The current price of TYRA is 11.06 USD — it has increased 2.6 % in the last trading day.

What is Tyra Biosciences Inc (TYRA)'s business?

What is the price predicton of TYRA Stock?

What is Tyra Biosciences Inc (TYRA)'s revenue for the last quarter?

What is Tyra Biosciences Inc (TYRA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Tyra Biosciences Inc (TYRA)'s fundamentals?

How many employees does Tyra Biosciences Inc (TYRA). have?
